<DOC>
	<DOCNO>NCT01676688</DOCNO>
	<brief_summary>The purpose study collect safety data ALFALASTIN® infusion perform home out-of hospital location .</brief_summary>
	<brief_title>Safety Study Alfalastin ( Human Alpha-1 Antitrypsin ) Administered Home</brief_title>
	<detailed_description>Non interventional , observational , longitudinal , prospective , multicenter , non comparative study .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Participation Criteria : Patients 18 y.o , suffer severe form primary alpha1 antitrypsin deficiency , phenotype PiZZ PiSZ pulmonary emphysema , currently treat per routine practice , week , ALFALASTIN® home outofhospital location sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>alpha-1 antitrypsin</keyword>
	<keyword>deficiency</keyword>
	<keyword>Alfalastin</keyword>
	<keyword>safety</keyword>
</DOC>